famotidine has been researched along with Hemorrhage, Peptic Ulcer in 28 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of intravenous famotidine at a conventional dose of 40 mg/day on 24-h intragastric pH in patients with a bleeding duodenal ulcer, and to determine the dose required to maintain gastric pH > 6 by use of a Gastrojet (MIC, Switzerland) device (a pH meter-controlled programmable pump)." | 9.08 | Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer. ( Delchier, JC; el Amine, I; Elouaer-Blanc, L; Lamarque, D; Roudot-Thoraval, F; Stanescu, L, 1995) |
| "A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients." | 9.08 | [Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995) |
| "We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated." | 7.69 | [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994) |
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| "From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| "To evaluate the effect of intravenous famotidine at a conventional dose of 40 mg/day on 24-h intragastric pH in patients with a bleeding duodenal ulcer, and to determine the dose required to maintain gastric pH > 6 by use of a Gastrojet (MIC, Switzerland) device (a pH meter-controlled programmable pump)." | 5.08 | Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer. ( Delchier, JC; el Amine, I; Elouaer-Blanc, L; Lamarque, D; Roudot-Thoraval, F; Stanescu, L, 1995) |
| "A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients." | 5.08 | [Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995) |
| "We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated." | 3.69 | [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994) |
| "Famotidine was superior to rebamipide in treating NSAID-associated mucosal lesions." | 2.72 | Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy). ( Akiyama, K; Ann, T; Fukui, H; Haruma, K; Kikuchi, E; Kinoshita, Y; Kojima, H; Matsumoto, M; Mitoro, A; Miyauchi, Y; Nakayama, M; Ono, H; Sakurai, G; Takakura, Y; Yajima, H; Yamao, J; Yoshida, M; Yoshikawa, M, 2006) |
| "Famotidine was effective in greater than or equal to 88% of patients with peptic ulcers and in 78." | 1.27 | Clinical benefits of intravenously administered famotidine in the treatment of upper gastrointestinal hemorrhage caused by peptic ulcer and stress ulcer disease. ( Aoki, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.71) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 13 (46.43) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Matsueda, K | 1 |
| Toyokawa, T | 1 |
| Sakata, M | 1 |
| Fujita, I | 1 |
| Horii, J | 1 |
| Abe, Y | 1 |
| Araki, T | 1 |
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 2 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Chan, FK | 1 |
| Kyaw, M | 1 |
| Tanigawa, T | 1 |
| Higuchi, K | 1 |
| Fujimoto, K | 1 |
| Cheong, PK | 1 |
| Lee, V | 1 |
| Kinoshita, Y | 2 |
| Naito, Y | 1 |
| Watanabe, T | 1 |
| Ching, JY | 1 |
| Lam, K | 1 |
| Lo, A | 1 |
| Chan, H | 1 |
| Lui, R | 1 |
| Tang, RS | 1 |
| Sakata, Y | 1 |
| Takeuchi, T | 1 |
| Handa, O | 1 |
| Nebiki, H | 1 |
| Wu, JC | 1 |
| Abe, T | 1 |
| Mishiro, T | 1 |
| Ng, SC | 1 |
| Arakawa, T | 1 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Tsay, FW | 1 |
| Cheng, JS | 1 |
| Liu, CP | 1 |
| Lai, KH | 1 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Lwin, AA | 1 |
| Lin, HJ | 1 |
| Tsai, JJ | 1 |
| Evseev, MA | 2 |
| Ivakhov, GB | 1 |
| Golovin, RA | 1 |
| Sakurada, T | 1 |
| Kawashima, J | 1 |
| Ariyama, S | 1 |
| Kani, K | 1 |
| Takabayashi, H | 1 |
| Ohno, S | 1 |
| Kato, S | 1 |
| Yakabi, K | 1 |
| Liu, CC | 1 |
| Lee, CL | 1 |
| Chan, CC | 1 |
| Tu, TC | 1 |
| Liao, CC | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Korukov, B | 1 |
| Ognianov, S | 1 |
| Kostadinova, R | 1 |
| Gerzilov, P | 1 |
| Ivanov, A | 1 |
| Iarŭmov, N | 1 |
| Kamada, T | 1 |
| Hata, J | 1 |
| Kusunoki, H | 1 |
| Kido, S | 1 |
| Hamada, H | 1 |
| Aoki, R | 1 |
| Nishida, T | 1 |
| Komoto, K | 1 |
| Todo, H | 1 |
| Sumioka, M | 1 |
| Tanimoto, T | 1 |
| Sanuki, E | 1 |
| Sumii, K | 1 |
| Ogoshi, H | 1 |
| Hidaka, T | 1 |
| Dongmei, Q | 1 |
| Chayama, K | 1 |
| Haruma, K | 2 |
| Gostishchev, VK | 1 |
| Yamao, J | 1 |
| Kikuchi, E | 1 |
| Matsumoto, M | 1 |
| Nakayama, M | 1 |
| Ann, T | 1 |
| Kojima, H | 1 |
| Mitoro, A | 1 |
| Yoshida, M | 1 |
| Yoshikawa, M | 1 |
| Yajima, H | 1 |
| Miyauchi, Y | 1 |
| Ono, H | 1 |
| Akiyama, K | 1 |
| Sakurai, G | 1 |
| Takakura, Y | 1 |
| Fukui, H | 1 |
| Ojiako, K | 1 |
| Shingala, H | 1 |
| Schorr, C | 1 |
| Gerber, DR | 1 |
| Carlson, RW | 1 |
| Baker, L | 1 |
| Andhavarapu, S | 1 |
| Delchier, JC | 1 |
| el Amine, I | 1 |
| Roudot-Thoraval, F | 1 |
| Elouaer-Blanc, L | 1 |
| Lamarque, D | 1 |
| Stanescu, L | 1 |
| Maculotti, L | 1 |
| Pradella, P | 1 |
| Busam, J | 1 |
| Garbe, WE | 1 |
| Zeltsman, D | 1 |
| Rowland, M | 1 |
| Shanavas, Z | 1 |
| Kerstein, MD | 1 |
| Grigor'ev, PI | 1 |
| Grinberg, AA | 1 |
| Toguzova, DA | 2 |
| Iakovenko, AV | 1 |
| Lopatina, IV | 1 |
| Pleshkov, VG | 1 |
| Afanas'ev, VN | 1 |
| Ovsiankin, AV | 1 |
| Shlevkov, BA | 1 |
| Abramova, LA | 1 |
| Nikiforov, PA | 1 |
| Bazarova, MA | 1 |
| Nikitina, SA | 1 |
| Osin, VL | 1 |
| Shugurov, VA | 1 |
| Walt, RP | 1 |
| Cottrell, J | 1 |
| Mann, SG | 2 |
| Freemantle, NP | 1 |
| Langman, MJ | 1 |
| Fullarton, GM | 1 |
| Macdonald, AM | 1 |
| McColl, KE | 1 |
| Aoki, T | 2 |
| Friedl, W | 1 |
| Krier, C | 1 |
| Dammann, HG | 1 |
| Müller, P | 1 |
| Simon, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186] | Phase 3 | 264 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 trials available for famotidine and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2 | 2017 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Comparison of adjuvant therapies by an H2-receptor antagonist and a proton pump inhibitor after endoscopic treatment in hemostatic management of bleeding gastroduodenal ulcers.
Topics: Chemotherapy, Adjuvant; Enzyme Inhibitors; Famotidine; Female; Gastrointestinal Hemorrhage; Hemostas | 2012 |
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Breath Tests; Carbolines; Clarithromycin; Drug Therapy, Co | 2003 |
[Study on the efficacy of famotidine (Quamatel) in the complex treatment of erosive gastroduodenitis, stress stomach ulcer and peptic duodenal ulcer].
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Bulgaria; Duodenal Ulcer; Famotidine; Female; Gas | 2004 |
Effect of famotidine on recurrent bleeding after successful endoscopic treatment of bleeding peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents; Blood Transfusion; Endoscop | 2005 |
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Famotidine; Female; Gastric Mu | 2006 |
Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer.
Topics: Adult; Aged; Duodenal Ulcer; Famotidine; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; I | 1995 |
[Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer].
Topics: Duodenal Ulcer; Famotidine; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Ranitidine | 1995 |
Continuous intravenous famotidine for haemorrhage from peptic ulcer.
Topics: Aged; Aged, 80 and over; Famotidine; Female; Gastric Mucosa; Hemoglobins; Humans; Infusions, Intrave | 1992 |
Controlled study of the effects of intravenous famotidine on intragastric pH in bleeding peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Famotidine; Humans; Hydrogen-Ion Concentration; | 1991 |
Treatment of upper gastro-intestinal bleeding with the H2-receptor antagonist famotidine.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Multicent | 1989 |
[I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Critical Care; Double-Blind Method; Famotidine; G | 1985 |
14 other studies available for famotidine and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
Hemorrhagic Stress-induced Gastric Ulcer in a Healthy Toddler.
Topics: Acute Disease; Endoscopy; Famotidine; Female; Gastrointestinal Hemorrhage; Humans; Infant; Peptic Ul | 2018 |
Famotidine versus pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Illness; Famotidine; Histamine H2 Antagonists; Hum | 2008 |
Skeptical that pantoprazole dose can prevent bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Hu | 2008 |
[Antisecretory therapy strategy for patients with bleeding and perforated gastroduodenal ulcers].
Topics: Antacids; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer | 2009 |
[Antisecretory therapy as a component of hemostasis in acute gastroduodenal ulcer bleedings].
Topics: Acute Disease; Anti-Ulcer Agents; Famotidine; Gastrointestinal Agents; Histamine H2 Antagonists; Hum | 2005 |
Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Famotidine; Histamine H2 Antagonists; Humans; Middle | 2008 |
Bleeding in the upper part of the gastrointestinal tract due to stress ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Famotidine; Histamine H2 Antagonists; Humans; Pantoprazole; | 2008 |
[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison].
Topics: Aged; Aged, 80 and over; Aluminum Hydroxide; Antacids; Dose-Response Relationship, Drug; Drug Admini | 1994 |
Is the incidence of hemorrhagic stress ulceration in surgical critically ill patients affected by modern antacid prophylaxis?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents; Cimetidine; Critical Care; | 1996 |
[Conservative treatment of ulcer hemorrhage with histamine H2 antagonists].
Topics: Adolescent; Adult; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Follow-Up Studies; Hista | 1997 |
[Famotidin (quamatel) in the treatment of gastroduodenal ulcer].
Topics: Adult; Drug Administration Routes; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Female; | 2000 |
[Experience in clinical use of quamatel in upper gastrointestinal hemorrhage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Duodenal Ulcer; Famotidine; Female; Gastroin | 2001 |
[H2 blockers in the treatment of bleeding gastroduodenal ulcers].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Duodenoscopy; Famotidine; Female; Gastro | 2001 |
Clinical benefits of intravenously administered famotidine in the treatment of upper gastrointestinal hemorrhage caused by peptic ulcer and stress ulcer disease.
Topics: Endoscopy; Famotidine; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Peptic Ulcer Hemorr | 1987 |